Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?
Joia Kai Capocchi(University of California, Irvine), David A. Jett(National Institute of Neurological Disorders and Stroke), Claudia Figueroa‐Romero(University of Michigan), Yvonne M. Nolan(University College Cork), Stefanie Grabrucker(University College Cork), Gina Faraci(University of California, Irvine), Jason A. Rothman(University of California, Riverside), Katrine Whiteson(University of California, Irvine), David M. Holtzman(Hope Center for Neurological Disorders), Sage J. B. Dunham(University of California, Irvine), Dong-oh Seo(Washington University in St. Louis), Rima Kaddurah‐Daouk(Duke University)
Cited by 5
Related Papers
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
|Immunity|2017|3k
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
|Stroke|2006|1.7k
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
|Cold Spring Harbor Perspectives in Medicine|2012|787